Click HERE to register.

Also available via Zoom Video Conferencing

This year’s symposium will discuss current state-of-the-art diagnostic and therapeutic approaches related to the recent advances in molecular testing and drug development in the field of acute leukemia and myeloproliferative disorders. There will be an emphasis on available opportunities to improve outcomes of patients with acute leukemia and myeloproliferative disorders with the optimal use of approved therapies and multidisciplinary supportive care and toxicity management.

Target Audience

This symposium is intended for physicians in the specialties of adult and pediatric hematology/oncology as well as pathology/microbiology; pharmacists; nurse practitioners; physician assistants; nurses; residents; and fellows who work with patients diagnosed with leukemia and myeloproliferative disorders.

Symposium Objectives

At the conclusion of this symposium, the participant should be better able to:

1. Discuss state-of-the-art management of myeloproliferative disorders
2. Identify the role of validated tools in symptom assessment among patients with myeloproliferative disorders including myelofibrosis
3. Identify failure of frontline therapy and intolerance to allow timely selection of optimal second-line treatment in myeloproliferative disorders
4. Recognize the role of flow cytometric, genetic and molecular profiling in selecting therapy and assessing minimal residual disease
5. List the novel therapies approved for Acute Lymphocytic Leukemia (ALL), including specific indications of various treatments
6. Recall management of toxicities associated with novel drugs used for ALL
7. Describe the role of allogeneic hematopoietic cell transplant in the management of acute leukemias and myelofibrosis
8. List the novel therapies approved for Acute Myeloid Leukemia (AML), including specific indications of various treatments
9. Recall management of toxicities associated with novel drugs used for AML
10. Discuss survivorship issues among young leukemia survivors
11. Discuss state-of-the-art management of Acute Promyelocytic Leukemia (APL)

Continuing Education Credits - Physicians

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.